Financebotresearch desk研究台

INGR › analyze

INGR · Analyze

ACCUMULATE Consumer

Price (2026-08-28, pre-market): $103.50 · MktCap $6.53B · EV $7.36B · 52wk range $94.44–$130.48 (re-tested the 52wk low twice in the last four months per Investing.com low-print alerts)

0. Knowledge check

python .mcp/kb.py find INGR → no matches, first coverage of this name. Knowledge/INDEX.md carries no Consumer-Defensive/packaged-foods theme sweep and no INGR-specific note, so this report derives fresh rather than citing a prior conclusion.

Pitfalls checked before trusting vendor numbers (INGR is a US-domiciled NYSE common stock, not an ADR — the ADR-specific pitfalls in the Playbook do not apply):

  • pitfall-vendor-forward-eps-is-the-wrong-fiscal-year fired again. Yahoo's forwardPE 9.12x prices forwardEps $11.35 — reconstructing from the company's own reaffirmed FY2026 adjusted-EPS guide (~$10.00, band $9.60–10.30) and cross-checking epsCurrentYear/ priceEpsCurrentYear ($10.57 / 9.79x) confirms the vendor's headline "forward" figure is FY2027, not FY2026. The true current-year multiple is ~9.8–10.4x, not 9.12x. This report uses the corrected current-year figure throughout and sets the watchlist-style trim on ttm, per the pitfall's own recommendation, rather than on the mislabeled forward field.
  • pitfall-roicai-fcf-field-returns-ocf confirmed. roic.ai's cf_free_cash_flow for INGR equals cf_cash_from_oper exactly in both years pulled ($944M = $944M FY25; $1,436M = $1,436M FY24) because cf_cap_expenditures returns null. roic.ai's "FCF" is OCF, not FCF. fin.py's OCF-minus-capex figures ($511M FY25, $1,141M FY24) are used as the authoritative FCF series below.
  • pitfall-roicai-free-plan-caps-history-at-two-years — confirmed again; roic.ai returned only FY2024–FY2025 on every ratio pull. Multi-year trend work below leans on fin.py's 4-year annual window plus web-sourced 5-year cash-flow data (stockanalysis.com), not roic.ai depth.
  • principle-down-a-lot-is-not-cheap — applied directly. INGR is 21% off its 52wk high, which says nothing on its own; the Graham/DYT work below checks it against its own multiple band instead of the drawdown.

No note yet exists on INGR or on the "processed-ingredients + GLP-1 demand risk" field — worth a /note after this report closes (left to the orchestrator per scope lock).

1. Fundamentals

Snapshot

Metric Value Metric Value
P/E (ttm) 11.4x P/E (current-FY, corrected) 9.8–10.4x (not the vendor's 9.12x — see above)
P/B 1.44 EV/EBITDA 6.4x
Gross margin (FY25) 25.3% Operating margin (FY25) 13.6% (roic.ai) / 12.6% (fin.py, GAAP)
Net margin (ttm) 8.2% ROE 13.7–17.8% (Yahoo / roic.ai FY25)
ROIC (roic.ai, FY25) 12.3% (vs. 10.2% FY24 — 2yr window only, see pitfall above) D/E 39.4%
Net debt / EBITDA (today, pre-deal) 0.61x Debt/Assets 25.0%
Div yield 3.13% 5yr avg div yield 2.70%
Payout ratio (GAAP) 36% Shares out 63.06M (falling)

Income statement trend (annual)

2022 2023 2024 2025
Revenue $7.95B $8.16B $7.43B $7.22B
Gross margin 18.7% 21.4% 24.1% 25.3%
Net income $492M $643M $647M $729M
Diluted EPS $7.34 $9.60 $9.71 $11.18
Diluted shares 67.0M 67.0M 66.6M 65.2M

Four straight years of gross-margin expansion (18.7% → 25.3%) is the FY22–25 headline — but it inverted in the first two quarters of 2026 (see §4, Sentiment): Q1'26 gross margin 22.4%, Q2'26 23.0%, both below the FY25 annual average, and quarterly diluted EPS has fallen every quarter for a year straight: $2.99 (Q2'25) → $2.61 → $2.56 → $2.22 → $1.78 (Q2'26), a ~40% peak-to-trough decline in quarterly EPS. This is the reason earningsGrowth (yoy) reads −41% in the vendor snapshot — it is real, not a data artifact.

Free cash flow — volatile, working-capital-driven, not a clean compounder

2021 2022 2023 2024 2025
OCF $392M $152M $1,057M $1,436M $944M
Capex -$300M -$300M -$314M -$295M -$433M
FCF $92M -$148M $743M $1,141M $511M

No honest 5–8yr FCF CAGR exists here — the series runs near-zero-to-negative in 2021–22 (a corn/tapioca input-cost spike consumed cash in working capital) before normalizing sharply in 2023–24 and dipping again in 2025 as capex stepped up ~45% above its historical ~$300M run-rate. Forcing a CAGR off a near-zero 2021 base would be false precision; the honest read is FCF is a commodity-cycle function of working capital and input costs, not a smooth growth line — and the Q1–Q2 2026 margin compression (see §4) plus an elevated capex run-rate raise real risk that 2026 FCF looks more like 2021–22 than 2023–24. This is the single most important fact the market may be pricing.

Capital allocation (FY2025, $944M OCF)

Capex 46% → dividends 22% → buybacks 24% → net debt roughly flat (issued $405M, repaid $449M). Historically disciplined: modest buybacks (share count down ~0.9%/yr, not aggressive), a steadily-raised dividend, near-zero net debt growth, and no meaningful M&A prior to 2026. That changes completely with the Tate & Lyle acquisition (see §4) — a $5.0B all-cash deal funded almost entirely by new debt and a $4.225B committed bridge facility, taking pro forma net debt/EBITDA from 0.6x today to ~3.0x at close, with a stated (not yet demonstrated) path back to 2.5x within 18 months. Applying the pattern-deleveraging-target-that-needs-an-asset-sale arithmetic: required paydown of roughly $0.9B (3.0x → 2.5x on ~$1.8B combined EBITDA) against an ~18-month window implies ~$600M/yr of debt paydown capacity is needed — plausible against a combined entity generating well over $1B of FCF in a normal year, but tight against INGR's own FY2025 FCF of just $511M and a currently-deteriorating margin trend. This is a real, quantifiable execution risk, not a hidden one — management has stated the target and the mechanism (organic cash flow + $130M run-rate synergies by 2030) rather than an unstated asset sale, so the pattern's literal "hidden filler" conclusion doesn't apply, but the tightness of the math is the risk to watch.

Dividend-grower overlay (this is a dividend payer — overlay applies)

10 consecutive years of dividend increases, quarterly rate $0.45 (2016) → $0.82 (2026), a ~6.4% 10yr dividend CAGR. FCF payout ratio has ranged from N/A (FCF negative, 2022) to 18% (2024) to 41% (2025) — rising but still comfortable, and the GAAP payout ratio (36%) leaves ample room even if FCF stays depressed through the M&A integration window. The dividend is safe independent of the M&A thesis — a distinct finding from whether the stock re-rates.

2. Moat & Competitive Advantage

Moat source: switching costs, not scale. Once a specialty starch, texturant, or sweetener is formulated into a customer's recipe, re-qualifying an alternative ingredient risks taste, texture, shelf-life, and regulatory-label changes — real friction that protects margin in the Texture & Healthful Solutions segment (the growth engine, the segment reported growing through the recent quarter). The Food & Industrial Ingredients — LATAM / US-Canada segments are commodity wet-milling businesses where Ingredion competes on scale against ADM and Cargill, both of which have superior logistics and cost scale — this layer has cost-advantage dynamics, not switching-cost dynamics, and it is the layer showing the current margin pressure (Argo facility manufacturing issues, softer U.S. demand, Mexico FX/macro).

Adversarial stress-test. A well-funded rival could contest either layer separately relatively easily (ADM/Cargill on commodity scale; Kerry/Givaudan/IFF on specialty science) but contesting both simultaneously at Ingredion's combined scale is harder — which is exactly the logic behind the Tate & Lyle acquisition: it is explicitly a bet to build critical mass in the specialty layer (where the real moat lives) rather than defend the commodity layer, which management appears to implicitly treat as a slower-growing, more cyclical base business.

Disruption vectors, 5–10yr: - GLP-1 / weight-loss-drug adoption is a genuine, slow-moving demand headwind specifically for caloric sweeteners (HFCS, glucose syrups) — current estimated drag on total food demand is small (~0.25%, ~12% US adoption), but it compounds as adoption rises and it falls disproportionately on exactly the commodity sweetener SKUs in the FII segments, not on the texturant/health-solutions side. This is a real multi-year structural risk, not a today problem. - Tapioca cost inflation (+40% YTD) is commodity-cyclical, not structural, but it is the proximate driver of $0.34/share of the recent earnings miss and won't resolve on a fixed timeline. - Regulatory/clean-label tailwind (sugar-reduction, non-GMO, biomaterials) favors Ingredion's specialty pivot and is a genuine multi-year tailwind, not a risk.

Evergreen assessment: moderately evergreen, mix-shifting. Food ingredients are not going away, but the profit pool is shifting from caloric commodity sweeteners toward texture/health solutions — which is precisely the shift the Tate & Lyle deal accelerates. The moat is real where formulation lock-in exists and weaker where Ingredion is a pure commodity processor.

3. Valuation

Applied conditionally: Ingredion is a mature, moderate-growth, dividend-paying industrial — Graham + Bogle + DYT all apply; DDM applies but is presented with a wide band given how sensitive it is to the discount-rate/growth-rate spread on a ~3% yielder.

Model Inputs / assumptions Output
Graham IV √(22.5×EPS×BVPS) BVPS $71.70. Using ttm (depressed) diluted EPS $9.09 → $121. Using FY26 guided/consensus adjusted EPS $10.00–10.57 → $127–131 $121–131
Bogle Expected Return Yield 3.1% + conservative organic earnings growth 4–5% (ex-M&A optionality) ± multiple re-rating (0 if overhang persists through the H2'27 close, +3–5%/yr if the multiple normalizes toward its own quieter-decade range once integration risk clears) ~7–9% base case, ~10–13% upside case
DYT Current yield 3.13% vs. 5yr avg 2.70% — yield ~16% above its own band, and the elevation is price-driven with no dividend cut (10 straight years of raises) — the non-inverted, genuine-signal case per pitfall-dyt-inverts-when-price-caused-the-yield Modestly positive value signal
DDM (Gordon growth) D1 ≈ $3.41 (current $3.28 grown 4%). r=8%/g=4% → $85; r=7.5%/g=4.5% → $114 $85–115, low-confidence — output is dominated by the r−g spread assumption, treated as a loose sanity check only, not a primary driver

Fair value range: $115–135, weighting Graham (highest — profitable, real book value, a value-tilted name) and Bogle most heavily, with DYT as corroboration and DDM as a wide guardrail. At $103.50 the stock sits roughly 10–20% below this range — consistent with the "quality on sale near 52wk low" premise, but the discount is not free money: a real, unresolved margin question (§1) and a real, quantifiable leverage step-up (§1/§4) explain a meaningful share of the gap, not just sentiment overreaction.

Historical P/E band note: third-party sources quote 5yr/10yr average P/E anywhere from ~15x to ~25x, but several of those averages are distorted by quarters with near-zero trailing EPS (one source shows a 224.8x print in Mar-2021 — the same 2021 margin trough visible in the FCF table above). Treat those averages skeptically rather than as a clean band; the more defensible anchor is the Graham/DDM work above, not a vendor-quoted historical multiple.

4. Sentiment & Intelligence — why INGR is near its 52wk low right now

Two distinct forces are compounding, and untangling them is the crux of this call.

(1) Four straight quarters of margin/EPS deterioration, driven by: - Argo, Illinois manufacturing issues — an operational/idiosyncratic outage, plausibly transient. - Softer demand in Food & Industrial Ingredients — U.S./Canada. - Mexico FX and macro headwinds in the LATAM segment. - Tapioca costs up >40% since the start of 2026 — a commodity input-cost spike, the single largest quantified drag ($0.34/share in Q2'26 alone). Management reaffirmed full-year adjusted EPS guidance of ~$10 through both Q1 and Q2 2026 prints, framing this as manageable and largely transient. The Q2 print beat consensus EPS while missing gross-margin estimates significantly — a genuine "which number do you believe" tension that this report resolves by weighting the margin trend over the EPS beat, since EPS was cushioned by FX, other income, buybacks, and lower financing costs rather than by the core business strengthening.

(2) The Tate & Lyle acquisition, announced June 8, 2026 — this is the dominant, underappreciated catalyst and the one this report weighs most heavily: - All-cash deal, ~£3.7B ($5.0B) enterprise value, 595p/share, a 59% premium to Tate & Lyle's pre-announcement price. - Financed via a $4.225B committed 364-day bridge facility plus existing cash and new debt — essentially no equity component, so no near-term dilution risk from the deal itself, but a sharp leverage step-up (0.6x → ~3.0x net debt/EBITDA at close). - Close expected H2 2027 — over a year of regulatory/shareholder/court process ahead, meaning the leverage and integration overhang is a multi-quarter holding-period risk, not a one-print event. - Combined entity: ~$10B revenue, ~$1.8B adjusted EBITDA (18.1% margin), run-rate synergies of ~$130M targeted by end-2030. - Oppenheimer downgraded INGR to Perform from Outperform explicitly citing deal complexity and demand-challenge concerns — this is the analyst-community read driving part of the de-rating, distinct from the margin story above.

Insider activity: neutral, not a golden flag. CEO Zallie has sold steadily through 2025–2026 (largely 10b5-1/RSU-vesting-linked sales at a range of prices from $88 to $137), and directors show routine stock-award grants plus small gift/tax-related transactions. No notable insider buying at or near the 52wk low was found — this doesn't corroborate the "opportunistic dip" read the way insider buying would, but routine executive selling on vesting is also not a red flag on its own.

Verdict on "cyclical/opportunity vs. structural/trap": This is a genuine close call, weighted toward cyclical-with-a-real-tail-risk rather than a clean trap. The margin drivers (Argo, tapioca, Mexico FX) read as commodity-cyclical and plausibly transient; the moat (switching costs in specialty) is intact and the strategic logic of the deal (build specialty scale before ADM/Cargill/ Kerry do) is sound. But the leverage step-up is real, multi-year, and not yet de-risked — a credit-rating action, a synergy miss, or a slower-than-planned deleveraging path would each be a genuinely bad outcome that the current discount only partially prices.

5. Synthesis — weighted verdict

Weighting rationale: INGR is a mature, dividend-paying, moderate-growth industrial — per analysis_notes.md §5, Fundamentals + Valuation should outweigh Moat/Sentiment disruption fears for this archetype. Applied here with one adjustment: the M&A leverage step-up is a Fundamentals fact, not a Sentiment mood, so it is weighted inside Fundamentals rather than discounted as noise.

Lens Read Weight
Fundamentals Historically disciplined capital allocator, safe dividend, but real 2026 margin deterioration + a genuine leverage step-up ahead (0.6x → 3.0x) High
Valuation Trades ~10–20% below a conservatively-built $115–135 fair-value range on Graham/Bogle/DYT High
Moat Real (switching costs, specialty pivot) where it matters, weaker (commodity scale) where the current pain is concentrated Medium
Sentiment Margin miss + M&A-complexity downgrade explain the drawdown; no insider-buying corroboration Medium

Named tensions: 1. EPS beat vs. margin miss, same quarter — resolved here by weighting margin (the leading indicator) over EPS (cushioned by non-operating items). 2. Valuation says cheap; the M&A math says the risk is real, not manufactured — this is the central reason conviction sits at 6/10 rather than higher: the discount is partly justified, not purely a sentiment overreaction. 3. Dividend safety vs. thesis safety are different questions — the dividend is safe on its own (36% GAAP payout, 10yr raise streak) independent of whether the acquisition thesis works.

Verdict: ACCUMULATE, conviction 6.0/10. Good business, real moat in its growing segment, historically disciplined balance sheet, trading modestly below a conservative fair-value estimate, with a safe and growing dividend — but the market is also pricing a genuine, multi-quarter execution risk (leverage step-up, integration, a not-yet-stabilized margin trend) that won't fully resolve before the deal closes in H2 2027. This is close enough to call either way; ACCUMULATE (build gradually, don't back up the truck) reflects that balance better than a full BUY.

Entry zone: $95–108 (current price already sits inside this zone — no need to chase, but no urgency to wait for a much deeper dip either, since the fair-value case doesn't require one). Trim: 13x ttm (adjusted-EPS basis once the deal is further de-risked; set on ttm rather than the vendor's fwd field per the fiscal-year mislabel found in §0).

Key risks that break this thesis: 1. Leverage/integration risk — if FY2026 organic FCF stays depressed (echoing 2021–22 rather than 2023–24) at the same time pro forma leverage steps up to 3.0x, the 18-month deleveraging path tightens further and a credit-rating action or a slower deleveraging timeline becomes the likely outcome, keeping the multiple compressed well past the eventual H2 2027 close. 2. Margin trend fails to stabilize — if the Q3/Q4 2026 prints show gross margin continuing below the FY2025 25.3% run-rate (rather than the Argo/tapioca/Mexico drivers proving transient), the Graham IV inputs built on a ~$10 normalized EPS are too generous and fair value should be re-cut toward the ttm-EPS-only $121 figure or lower.

Sources: python .mcp/fin.py INGR --news; roic.ai get_profitability_ratios/get_per_share_data/ get_credit_ratios/get_cash_flow (NYSE:INGR); Yahoo Finance MCP (get_stock_info, get_financial_statement quarterly, get_stock_actions, get_holder_info insider_transactions); stockanalysis.com cash-flow statement (5yr FCF history); WebSearch — Ingredion Q2 2026 earnings coverage (StockStory, Motley Fool, Simply Wall St), Ingredion/Tate & Lyle 8-K and IR press release, GlobeNewswire deal announcement, GLP-1/food-demand coverage (FoodDive, ConfectioneryNews), competitive-landscape coverage (Kavout, KoalaGains).